Ronald Muhlenkamp recent buys & sells (2022 Q3)
Muhlenkamp & Co
Muhlenkamp & Co Portfolio Changes
Purchase & sale details
- Portfolio value:
- $223.96M (+$10M)
- Previous value:
- $213.55M
- # of changes:
- 26
- New positions:
- 1
- Reported for:
- 30 Sep 2022 (Q3)
- Latest filing date:
- 01 Nov 2022
Muhlenkamp & Co has disclosed a total of 26 changes to the portfolio in the (2022 Q3) SEC report(s): increased the number of shares of 22, bought 1 totally new, decreased the number of shares of 1 and completely sold out 2 position(s).
What stocks did Ronald Muhlenkamp buy in 2022 Q3?
During 2022 Q3 Ronald Muhlenkamp has bought 23 securities out of which top 5 purchases (by % change to portfolio) were (EQT) EQT Corp (added shares +0.36%), (OXY) Occidental Petroleum Corp (added shares +0.52%), (MCK) McKesson Corp (added shares +0.75%), (UNH) UnitedHealth Group Incorporated (added shares +0.86%) and (SPDN) Direxion Daily S&P 500 Bear 1X Shares (new buy).
What did Ronald Muhlenkamp invest in during 2022 Q3?
In the 2022 Q3 report(s) the following changes have been made to the top investments: (EQT) EQT Corp (added shares +0.36%), (OXY) Occidental Petroleum Corp (added shares +0.52%), (MCK) McKesson Corp (added shares +0.75%), (UNH) UnitedHealth Group Incorporated (added shares +0.86%) and (SPDN) Direxion Daily S&P 500 Bear 1X Shares (new buy).
26 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Direxion Daily S&P 500 Bear 1X Shares
|
new
|
+652,921
|
652,921
|
+5.21%
|
$17.88
|
-52.57%($8.48)
|
5.21%
|
2022 Q3
|
~0.25 years
|
|
|
|
SPDR Gold Shares
|
+26.22%
|
+3,840
|
18,485
|
+0.27%
|
$154.67
|
+146.62%($381.43)
|
1.28%
|
2016 Q2
|
~6.00 years
|
|
|
|
Royal Gold Inc
|
+11.29%
|
+4,752
|
46,855
|
+0.2%
|
$93.82
|
+151.88%($236.32)
|
1.96%
|
2020 Q4
|
~2.00 years
|
|
|
|
Franco-Nevada Corp
|
+8.07%
|
+2,861
|
38,314
|
+0.15%
|
$119.49
|
+102.43%($241.88)
|
2.04%
|
2020 Q4
|
~2.00 years
|
|
|
|
Schlumberger NV
|
+1.27%
|
+3,959
|
314,502
|
+0.06%
|
$35.90
|
+38.12%($49.58)
|
5.04%
|
2020 Q4
|
~2.00 years
|
|
|
|
Alerian MLP ETF
|
+1.05%
|
+2,957
|
284,057
|
+0.05%
|
$36.56
|
+43.41%($52.43)
|
4.64%
|
2018 Q1
|
~4.25 years
|
|
|
|
CVS Health Corp
|
+0.99%
|
+1,078
|
110,001
|
+0.05%
|
$95.37
|
-3.11%($92.41)
|
4.68%
|
2019 Q3
|
~3.00 years
|
|
|
|
Bristol-Myers Squibb Company
|
+0.94%
|
+1,197
|
128,753
|
+0.04%
|
$71.09
|
-14.68%($60.65)
|
4.09%
|
2019 Q4
|
~2.75 years
|
|
|
|
UnitedHealth Group Incorporated
|
+0.86%
|
+212
|
24,736
|
+0.05%
|
$505.05
|
-20.41%($401.95)
|
5.58%
|
2016 Q1
|
~6.25 years
|
|
|
|
McKesson Corp
|
+0.75%
|
+285
|
38,209
|
+0.04%
|
$339.87
|
+194.94%($1,002.41)
|
5.80%
|
2016 Q2
|
~6.00 years
|
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted. 2013 Q2 is the earliest period we have data for, so "2013 Q2*" means "2013 Q2 or earlier".